Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGM831 + NGM438 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- NGM Biopharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NGM831 + NGM438 + pembrolizumab is a combination therapy under investigation for the treatment of advanced or metastatic solid tumors. NGM831 and NGM438 are investigational monoclonal antibodies developed by NGM Biopharmaceuticals. Pembrolizumab, marketed as Keytruda, is an approved humanized monoclonal antibody that targets the programmed death receptor 1 (PD-1) on lymphocytes, functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. The combination aims to improve cancer immunotherapy outcomes by targeting multiple immune regulatory pathways in the tumor microenvironment[1][2][4][5][6].
- Other names
- none
02
Targets
LAIR1 (Leukocyte-associated immunoglobulin-like receptor 1)PDCD1 (Programmed cell death protein 1 receptor)LILRB4
Beyond the preview
Go deeper on NGM831 + NGM438 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGM831 + NGM438 + pembrolizumab.